Researchers Find Understudied Organ May Play Central Role in Aging and Cancer

For most of modern medicine's history, the thymus — a small, two-lobed gland tucked behind the breastbone — has been treated as biological waste. Doctors routinely removed it during cardiac surgeries. Textbooks described it as vestigial in adults, a gland that does its job training immune cells in childhood, then quietly atrophies into fat. That consensus is now fracturing.

Two studies published in Nature in March 2026, led by Hugo Aerts and colleagues at Mass General Brigham and Harvard Medical School, present the strongest evidence yet that thymic health in adults is tightly linked to longevity, cardiovascular disease, cancer risk, and response to immunotherapy [1][2]. The research, which used artificial intelligence to analyze CT scans of more than 31,000 people, found that individuals with well-preserved thymus glands were significantly less likely to die from nearly every major cause of death [3].

The implications are sweeping. If confirmed, the findings could reshape how physicians think about aging, cancer treatment, and immune surveillance — and explain why some people's immune systems hold up into old age while others collapse.

What the Thymus Does — and Why Medicine Ignored It

The thymus is the primary organ responsible for the maturation of T cells, a class of white blood cells essential for adaptive immunity. During childhood and adolescence, immature immune cells migrate from the bone marrow to the thymus, where they are trained to distinguish the body's own cells from foreign threats — viruses, bacteria, and cancer cells [4]. T cells that react to the body's own tissues are eliminated. Those that pass selection enter the bloodstream as functional defenders.

After puberty, the thymus begins to shrink in a process called thymic involution. Functional thymic tissue is gradually replaced by adipose (fat) tissue. By middle age, the gland is a fraction of its adolescent size. By the time a person reaches their 70s, the thymus is often almost entirely composed of fat [5].

This involution led most researchers and clinicians to conclude that the thymus was effectively dormant in adults. The assumption was so entrenched that surgeons frequently removed the gland during open-heart surgery — it sits directly in the surgical field — without concern for long-term consequences [6].

A 2016 paper in Frontiers in Immunology was aptly titled "The Thymus: A Forgotten, But Very Important Organ" [7]. That title captured the field's own frustration with decades of neglect.

The 2023 Wake-Up Call: Thymectomy and Mortality

The first major crack in the old consensus came in August 2023, when a study led by David Scadden at Massachusetts General Hospital was published in The New England Journal of Medicine. The researchers tracked 1,420 patients who had undergone thymectomy (surgical thymus removal) and compared them to 6,021 matched controls [6].

The results were striking. Within five years of surgery, patients who had lost their thymus were 2.9 times more likely to die from any cause (8.1% vs. 2.8%) and twice as likely to develop cancer (relative risk 2.0) [6]. Over longer follow-up, the elevated risks persisted: all-cause mortality carried a hazard ratio of 1.9, and cancer risk a hazard ratio of 1.3 [6]. When patients with preoperative cancer, infection, or autoimmune disease were excluded, thymectomy patients also showed a 50% higher rate of autoimmune disease (12.3% vs. 7.9%) [6].

A subgroup analysis of T cell production found that thymectomy patients, even 14 years after surgery, had consistently lower production of new T cells and higher levels of pro-inflammatory molecules in the blood [6].

Source: Kooshesh et al., NEJM (2023)

Data as of Aug 2, 2023CSV

The study triggered immediate reconsideration of routine thymectomy during cardiac surgery. A follow-up analysis published in Blood Advances in 2025 confirmed that thymectomy was associated with increased cancer mortality risk specifically, further strengthening the case that losing the thymus carries measurable consequences [8].

The 2026 Nature Studies: AI, CT Scans, and 31,000 Patients

The 2023 thymectomy study showed what happens when the thymus is removed. The 2026 Nature studies asked a different question: among people who still have their thymus, does its condition predict how well they age?

Hugo Aerts, director of the Artificial Intelligence in Medicine (AIM) Program at Mass General Brigham, led a team that developed a deep-learning framework trained on 5,674 thoracic CT scans. The system generated a continuous "thymic health score" from 0 to 1, reflecting the preservation of thymic structure and presumed function based on the organ's size, shape, and tissue composition [1][2].

The team then applied this score to two large prospective cohorts: 25,031 adults from the National Lung Screening Trial and 2,581 participants in the Framingham Heart Study [1]. The results were consistent across both populations.

Adults with the highest thymic health scores had approximately:

• 50% lower risk of all-cause mortality
• 63% lower risk of cardiovascular death
• 36% lower risk of developing lung cancer [1][3]

These associations held after adjusting for age, sex, smoking status, and other health factors [3].

Source: Bernatz et al., Nature (2026)

Data as of Mar 18, 2026CSV

In a companion paper, the team examined 3,476 cancer patients receiving immune checkpoint inhibitors — a class of immunotherapy drugs that work by unleashing the patient's own T cells against tumors. Patients with higher thymic health scores had a 37% lower risk of cancer progression and a 44% lower risk of death, again after controlling for patient demographics, tumor type, and treatment variables [2][9].

"The thymus has been overlooked for decades and may be a missing piece in explaining why people age differently," Aerts said [3].

The Proposed Biological Mechanism

The biological logic connecting the thymus to aging and cancer centers on T cell diversity. As the thymus involutes, its output of naïve T cells — freshly trained cells capable of recognizing new threats — declines sharply. The circulating T cell pool becomes increasingly dominated by memory cells from past infections, a phenomenon known as immunosenescence [5][10].

This loss of diversity has cascading effects. With fewer naïve T cells available, the immune system becomes less capable of recognizing and destroying cancer cells as they arise — a process called immunosurveillance. At the same time, the aging immune system tends to produce higher levels of chronic, low-grade inflammation (dubbed "inflammaging"), which itself promotes cancer and cardiovascular disease [5][10].

The 2026 studies found that chronic inflammation, smoking, and high body mass index were all associated with poorer thymic health, suggesting that systemic inflammatory burden may accelerate thymic involution — creating a feedback loop where inflammation damages the thymus, which in turn reduces immune function, which permits more inflammation [1][3].

The immunotherapy findings add another dimension. Immune checkpoint inhibitors depend on a patient having enough functional T cells to attack a tumor once the "brakes" are released. If the thymus is degraded and T cell diversity is low, there may simply not be enough cancer-reactive T cells to mount an effective response [2][9]. This could explain why immunotherapy works spectacularly in some patients and fails entirely in others.

The Research Gap: A Neglected Organ in Numbers

Despite its potential importance, the thymus has received far less scientific attention than comparably sized or functionally analogous organs. According to OpenAlex, approximately 48,400 papers have been published on thymus, aging, and cancer combined since 2011, with publication rates peaking at 6,061 papers in 2023 [11]. Research on thymus and immunotherapy specifically totals around 20,700 papers in the same period [11].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Source: OpenAlex

Data as of Jan 1, 2026CSV

By contrast, PubMed lists hundreds of thousands of papers on the liver and cancer or pancreas and cancer over similar timeframes. The disparity reflects decades of institutional disinterest. As the NIH's own Intramural Research Program noted, despite the thymus's "huge immunological impact," the organ lacked dedicated symposia until 2012, when the first NIH Thymus Symposium was convened [12].

Funding has been correspondingly limited. While the NIH has issued individual grants — such as a $3.5 million, five-year award to a UC Merced lab studying thymic function [13] — there is no dedicated NIH institute or major funding initiative focused on the thymus, unlike the National Heart, Lung, and Blood Institute or the National Cancer Institute's organ-specific programs. The 2026 studies were funded by the NIH, European Research Council, Deutsche Forschungsgemeinschaft, Lundbeck Foundation, and Novo Nordisk Foundation, reflecting the need for international support to sustain the work [1].

The Skeptics' Case: Correlation, Confounding, and Caution

Not all researchers are persuaded that the thymus is a causal driver of the outcomes observed. María Mittelbrunn, a researcher at the Spanish Research Council and Columbia University, offered a pointed counterargument in response to the 2026 findings.

"The thymus could be acting as a proxy for overall physiological health rather than determining it," Mittelbrunn told Scientific American. She suggested that what the AI scoring system captures may reflect "a broader state of low inflammation and better global organ function" rather than a thymus-specific effect [4].

This is a standard concern in observational epidemiology: the healthy thymus may be a marker of a generally healthy body, not the cause of that health. People who smoke less, weigh less, and have fewer comorbidities would be expected to have both better thymic health and better outcomes — and while the 2026 studies controlled for age, sex, and smoking, they could not fully account for every potential confounder [4][14].

Several specific experimental controls are absent from the current evidence base:

• No interventional data in humans: No study has shown that improving thymic function (through drugs, transplantation, or other means) leads to better health outcomes. The evidence remains observational [3][14].
• Confounding by prior treatments: In the immunotherapy cohort, patients' thymic health may have been affected by prior chemotherapy, radiation, or steroid use — all of which can damage the thymus and independently worsen outcomes [14].
• No longitudinal tracking of thymic change: The studies measured thymic health at a single time point. Whether the rate of thymic decline over time (rather than a snapshot) predicts outcomes remains unknown [14].
• Reverse causation: Poor health and subclinical disease could cause thymic atrophy, rather than thymic atrophy causing poor health [4].

The researchers themselves acknowledged these limitations. Aerts noted that the findings "will need to be confirmed in future studies" and that the imaging method "is not yet ready for routine clinical use" [3].

Demographic Patterns and Open Questions

The 2026 studies drew primarily from the National Lung Screening Trial, which enrolled adults aged 55–74 with significant smoking histories, and the Framingham Heart Study, a predominantly white cohort from the northeastern United States [1]. The immunotherapy cohort spanned multiple cancer types but was based in large academic medical centers [2].

This means the strongest data comes from older, smoking-exposed, predominantly white populations. Whether the associations hold to the same degree in younger adults, non-smokers, or more racially and ethnically diverse populations remains an open question. Thymic involution rates may vary across ancestral populations, though this has not been systematically studied at scale.

The studies found that smoking and high BMI were associated with worse thymic health [1][3], raising the possibility that some of the observed mortality differences reflect lifestyle factors rather than thymic function per se. Disentangling these effects will require studies in populations with different risk profiles.

Sex-based differences in thymic involution are known from animal models — female mice tend to retain thymic function longer than males — but the 2026 studies did not report sex-stratified results in detail beyond using sex as a covariate [5][10].

Thymus Regeneration: From TRIIM to Clinical Trials

If the thymus matters as much as the new data suggest, the obvious question is whether it can be restored. The most prominent effort to answer this is the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) program, led by Greg Fahy and his company Intervene Immune [15].

The original TRIIM trial, published in 2019, treated nine men aged 51–65 with a combination of recombinant human growth hormone, metformin, and DHEA. MRI imaging showed signs of thymic tissue regeneration, and participants' epigenetic clocks — molecular markers of biological age — reversed by an average of 2.5 years over the one-year treatment period [15]. The trial was small and lacked a placebo-controlled arm, but it generated significant interest.

The follow-up TRIIM-X trial (ClinicalTrials.gov: NCT04375657) is an expanded pilot study evaluating personalized dose combinations of the same agents. Intervene Immune was named a semifinalist in the XPRIZE Healthspan competition, advancing from a field of over 600 teams [15][16].

Other approaches under investigation include:

• Interleukin-7 (IL-7) therapy: IL-7 is a cytokine that promotes T cell development and survival. Clinical trials have tested IL-7 in HIV patients and post-transplant settings to boost T cell recovery [10].
• Keratinocyte growth factor (KGF): Shown in animal models to promote thymic epithelial cell regeneration after damage from chemotherapy or radiation [10].
• Sex steroid ablation: Since sex hormones contribute to thymic involution after puberty, temporary suppression of these hormones has shown thymic regrowth in animal models and early human studies [10].

None of these approaches has reached Phase III clinical trials for thymic regeneration specifically. The realistic clinical timeline from current research to approved therapeutics spans at least a decade, requiring progression through dose-finding trials, large randomized controlled trials, and regulatory review — with the added challenge that thymic health is not yet an established clinical endpoint that the FDA recognizes [14].

Why Was the Thymus Ignored?

The decades of neglect have specific institutional causes. First, thymic involution was interpreted through the lens of evolutionary biology: if the organ shrinks naturally, it must not be needed. This reasoning, while superficially logical, ignored the possibility that involution is a trade-off (reducing autoimmune risk) rather than evidence of irrelevance [7][12].

Second, the thymus was difficult to study. It sits deep in the chest, is hard to biopsy without surgery, and its output — naïve T cells — can only be measured indirectly through blood tests for T cell receptor excision circles (TRECs), a technically demanding assay [5]. Without easy measurement tools, researchers gravitated toward more accessible organs.

Third, funding structures favor organ systems with established disease constituencies and dedicated NIH institutes. The heart has the NHLBI. The brain has the NINDS and NIA. The thymus falls into an institutional gap — relevant to immunology, oncology, and gerontology, but claimed by none of them as a primary focus [12][13].

The 2023 NEJM thymectomy study and the 2026 Nature papers may be changing this calculus. The development of an AI-based scoring system that can assess thymic health from routine CT scans — images that already exist in the millions in hospital databases — removes one of the field's biggest practical barriers [1][2]. Researchers can now study thymic health retrospectively, at population scale, without requiring new imaging or biopsies.

What Comes Next

The field now faces several critical questions. Can interventional studies demonstrate that improving thymic function leads to better health outcomes, or will the thymus prove to be a useful biomarker rather than a therapeutic target? Will thymic health scoring be validated across diverse populations? And can the regenerative approaches currently in early-stage trials scale to clinical use?

For cancer treatment specifically, the most immediate application may be using thymic health scores to predict which patients are most likely to respond to immune checkpoint inhibitors — potentially sparing non-responders from ineffective treatment and its side effects [2][9]. This would require prospective validation trials, but the data infrastructure already exists.

For aging research, the thymus sits at an intersection that has long interested gerontologists: the relationship between immune decline and the diseases of aging. If thymic health proves to be more than a correlate — if it is genuinely a driver of immune aging — then interventions that preserve or restore it could address multiple age-related diseases simultaneously, rather than treating them one by one.

That is a large "if." But after decades of dismissal, the thymus is finally getting the attention the data suggest it deserves.